Ultragenyx Pharmaceutical (RARE) Total Liabilities (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Total Liabilities of $1.5 billion for Q1 2026, up 31.39% year-over-year from $1.2 billion in Q1 2025, and down 4.98% quarter-over-quarter from $1.6 billion in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Total Liabilities (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Total Liabilities for 14 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 31.39% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 31.39% YoY), while the FY2025 annual figure was $1.6 billion, up 29.33% from the prior year.
- Total Liabilities slipped to $1.5 billion in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $1.6 billion in Q4 2025 and bottomed at $587.6 million in Q1 2022.
- Historically, Total Liabilities has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 108.6% — and 2025, when it dropped 3.21%.
- Ultragenyx Pharmaceutical's Total Liabilities stood at $1.2 billion in 2022, then gained by 1.9% to $1.2 billion in 2023, then grew by 2.09% to $1.2 billion in 2024, then rose by 29.33% to $1.6 billion in 2025, then dropped by 4.98% to $1.5 billion in 2026.
- Business Quant data shows RARE's Total Liabilities at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 1.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Bn |
| Mar 31, 2026 | 1.53 Bn |
| Dec 31, 2025 | 1.61 Bn |
| Sep 30, 2025 | 1.17 Bn |
| Jun 30, 2025 | 1.15 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 1.24 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.19 Bn |
| Mar 31, 2024 | 1.17 Bn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.21 Bn |
| Jun 30, 2023 | 1.18 Bn |
| Mar 31, 2023 | 1.16 Bn |
| Dec 31, 2022 | 1.19 Bn |
| Sep 30, 2022 | 1.15 Bn |
| Jun 30, 2022 | 642.55 Mn |
| Mar 31, 2022 | 587.61 Mn |
| Dec 31, 2021 | 599.84 Mn |
| Sep 30, 2021 | 551.13 Mn |